Drug Delivery
Hydralese®Rx
Solesis’ Research & Development team has developed Hydralese®Rx, a novel polymer platform for drug delivery systems that enables the controlled release of active pharmaceutical ingredients (APIs). Hydralese®Rx offers unparalleled advantages over traditional polymers currently used in drug delivery devices, empowering the creation of innovative, custom-engineered drug delivery solutions for complex, long-acting therapeutic applications.
Learn more about Solesis’ Hydralese®Rx drug delivery technology as we build better solutions, together.
The Hydralese®Rx Difference
Solesis’ patented Hydralese®Rx platform provides a library of bioresorbable and biocompatible elastomers composed of poly(glycerol ester) urethanes (PGEUs). These versatile polymers enable controlled-release from days to months, supporting a broad range of drug delivery systems.
Backed by decades of research, Hydralese®Rx boasts tunable properties that make it an ideal excipient for various administration routes, including implantable devices, injectable formulations, and oral or transdermal drug delivery systems.
This versatility supports multiple therapeutic areas, from women’s health to therapies targeting the sensory organs, central nervous system, and endocrine system.
Examples of applications include:
Subcutaneous implants, such as rods or closed geometries, for pain management, HIV prevention, contraceptives, and multipurpose prevention therapy (MPT)
Microparticles, multi-particulate medication delivery systems for parenteral or oral administration
Gastroretentive devices, such as torus rings, flat rings, and star-shaped geometries designed for controlled oral delivery
Hydralese®Rx was developed to address key challenges therapy developers face during drug delivery device development, offering:
| Molecule Types | Biocompatible | Biodegradable | Linear Release Kinetics |
|---|---|---|---|
| Small molecule APIs | Minimal pH change observed in vitro during Hydralese®Rx degradation | Degradation timeframe of 3 to 12+ months; degrades into monomers metabolized by the body | Near-zero-order release kinetics |
| Large molecule APIs | No residual inflammation or fibrous encapsulation | ||
| Biologics | All tissues return to normal upon degradation of Hydralese®Rx after subcutaneous implantation in rats |
Small molecule APIs
Large molecule APIs
Biologics
| Highly Flexible | High Drug Loading | Shelf Stable | Variety of Manufacturing Processes |
|---|---|---|---|
| Flexible at high drug loadings; suitable for applicator use | Enables high drug loading up to 60% w/w in solvent-free formulations | Room-temperature and humidity shelf storage; compatible with terminal gamma sterilization; stable post-sterilization for up to 6 months |
|
Flexible at high drug loadings; suitable for applicator use
- Extrusion
- Molding
- Casting
- Coating
- Emulsion
- 3D Printing
- Foaming
We provide:
- In-house analytical testing and method validation
- ISO 7 and 8 cleanrooms
- In vitro release and polymer degradation testing
- Process development and optimization
We support your development through GLP and GMP phases, including:
- Discovery & development
- Preclinical research
- Phase I/II clinical development
- Technical transfer
- Scale up
